.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Chubb
Cipla
Novartis
Mallinckrodt
McKesson
Baxter
Harvard Business School
Teva
Fuji

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,001,876

« Back to Dashboard

Which drugs does patent 6,001,876 protect, and when does it expire?


Patent 6,001,876 protects LYRICA and is included in two NDAs. There have been two Paragraph IV challenges on Lyrica.

This patent has twenty-nine patent family members in twenty-three countries.

Summary for Patent: 6,001,876

Title: Isobutylgaba and its derivatives for the treatment of pain
Abstract:The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in pain therapy.
Inventor(s): Singh; Lakhbir (Cambridgeshire, GB)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/043,358
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-001Dec 30, 2004RXYesNo6,001,876► SubscribeY TREATMENT OF PAIN
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-001Dec 30, 2004RXYesNo6,001,876► SubscribeY MANAGEMENT OF FIBROMYALGIA
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-002Dec 30, 2004RXYesNo6,001,876► SubscribeY TREATMENT OF PAIN
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-002Dec 30, 2004RXYesNo6,001,876► SubscribeY MANAGEMENT OF FIBROMYALGIA
Pf Prism Cv
LYRICA
pregabalin
CAPSULE;ORAL021446-003Dec 30, 2004RXYesNo6,001,876► SubscribeY TREATMENT OF PAIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,001,876

PCT Information
PCT FiledJuly 16, 1997PCT Application Number:PCT/US97/12390
PCT Publication Date:January 29, 1998PCT Publication Number: WO98/03167

Non-Orange Book Patents for Patent: 6,001,876

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE41920Isobutylgaba and its derivatives for the treatment of pain► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,001,876

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal934061► Subscribe
Poland189872► Subscribe
Poland331325► Subscribe
New Zealand332762► Subscribe
Norway2008018► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Argus Health
Cerilliant
Express Scripts
Deloitte
Cantor Fitzgerald
Fuji
Johnson and Johnson
Colorcon
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot